MEDICATIONS

SGLT2 Inhibitors and Weight

Diabetes medications that promote weight loss by causing the kidneys to excrete excess sugar in urine, resulting in a modest caloric deficit and cardiovascular protection.

SGLT2 inhibitors are medications originally developed for type 2 diabetes that also help with weight loss. They work by causing your kidneys to remove excess sugar from your blood through urine, which means you lose calories along with the sugar. Common examples include dapagliflozin and empagliflozin.

SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce renal glucose reabsorption in the proximal tubule, inducing glycosuria that results in a net caloric loss of approximately 200–300 kcal/day. Clinical trials demonstrate a mean weight loss of 2–3 kg over 6–12 months, with effects persisting through 2+ years. The weight loss is modest, partially offset by compensatory hyperphagia, but the class also confers cardiovascular and renal protective benefits independent of glycaemic control.

For patients with obesity and concurrent type 2 diabetes or cardiovascular risk, SGLT2 inhibitors offer a dual benefit. At NuLifeCare Singapore, Dr. Joseph Wang can assess whether adding an SGLT2 inhibitor to your treatment plan provides meaningful metabolic and weight benefits.

⚕️

Medical Disclaimer

This library is for general education and does not replace individual assessment by a qualified healthcare professional. Always consult a doctor for medical advice, diagnosis, or treatment.

← Back to Weight Management Library